Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions

JAMA Oncol. 2017 Jan 1;3(1):18-20. doi: 10.1001/jamaoncol.2016.3112.
No abstract available

MeSH terms

  • Biomarkers*
  • Disease-Free Survival
  • Humans
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Neoplasm, Residual / pathology*

Substances

  • Biomarkers